Resumen

In the not so distant past, organs from hepatitis C infected donors were either discarded or rarely transplanted into HCV viremic recipients - but never allocated to non-infected patients. However, the simplicity, ease and unprecedented success rates of HCV direct acting antiviral regimens has raised the possibility of utilizing such organs in an attempt to expand the donor pool. The thinker trial reports the first of such attempts. However, caution must be exercised prior to the widespread adoption of such strategy.

Palabras clave: Hepatitis C transplantation kidney allografts direct acting antiviral agents.

2017-12-13   |   113 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.5. Septiembre-Octubre 2017 Pags. 702-703 Ann Hepatol 2017; 16(5)